emd1214063 and Pneumonia

emd1214063 has been researched along with Pneumonia* in 1 studies

Other Studies

1 other study(ies) available for emd1214063 and Pneumonia

Article	Year
Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report. International journal of molecular sciences, 2022, Oct-05, Volume: 23, Issue:19 The targeted agents capmatinib and tepotinib provide a new treatment for patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However, drug-induced pneumonitis is an uncommon but threatening adverse effect found in patients treated with both capmatinib and tepotinib. The safety of treating a patient with a MET inhibitor after drug-induced pneumonitis by another MET inhibitor remains unclear. Here, we present a case of a patient with NSCLC harboring a METex14 who was treated with a standard dose of tepotinib after advanced capmatinib-induced pneumonitis and did not present pneumonitis relapse. Tepotinib may be a safe option when medical professionals consider switching MET inhibitors after patients experience pneumonitis. Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Exons; Humans; Imidazoles; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Piperidines; Pneumonia; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Triazines	2022

Article

Year

Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.

International journal of molecular sciences, 2022, Oct-05, Volume: 23, Issue:19

The targeted agents capmatinib and tepotinib provide a new treatment for patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However, drug-induced pneumonitis is an uncommon but threatening adverse effect found in patients treated with both capmatinib and tepotinib. The safety of treating a patient with a MET inhibitor after drug-induced pneumonitis by another MET inhibitor remains unclear. Here, we present a case of a patient with NSCLC harboring a METex14 who was treated with a standard dose of tepotinib after advanced capmatinib-induced pneumonitis and did not present pneumonitis relapse. Tepotinib may be a safe option when medical professionals consider switching MET inhibitors after patients experience pneumonitis.

Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Exons; Humans; Imidazoles; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Piperidines; Pneumonia; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Triazines

2022